Get the Stockscreener App
1.81
11.71%
-0.24
After Hours:
1.80
-0.01
-0.55%
Gri Bio Inc stock is traded at $1.81, with a volume of 999.07K.
It is down -11.71% in the last 24 hours and up +43.08% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$2.05
Open:
$2.06
24h Volume:
999.07K
Relative Volume:
0.92
Market Cap:
$4.55M
Revenue:
-
Net Income/Loss:
$-8.26M
P/E Ratio:
-0.0338
EPS:
-53.609
Net Cash Flow:
$-12.17M
1W Performance:
+9.04%
1M Performance:
+43.08%
6M Performance:
-69.58%
1Y Performance:
-78.90%
1-Day Range:
$1.76
$2.06
1-Week Range:
$1.4683
$2.87
52-Week Range:
$1.10
$30.43
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
1.81 | 3.92M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
Order flow analysis tools used on GRI Bio Inc.July 2025 Retail & Consistent Profit Trade Alerts - Newser
Will breakout in GRI Bio Inc. lead to full recoveryGold Moves & Fast Exit and Entry Strategy Plans - Newser
Will earnings trigger a reversal in GRI Bio Inc.Insider Buying & Safe Capital Investment Plans - Newser
Ranking GRI Bio Inc. among high performing stocks via toolsQuarterly Trade Report & Precise Swing Trade Alerts - Newser
Will GRI Bio Inc. see short term momentumWeekly Volume Report & Weekly Market Pulse Updates - Newser
Will a bounce in GRI Bio Inc. offer an exitDay Trade & Reliable Breakout Stock Forecasts - Newser
GRI Bio Inc. stock prediction for this weekTrade Risk Report & Daily Price Action Insights - Newser
How institutional ownership impacts GRI Bio Inc. stockWeekly Trade Analysis & Free Expert Approved Momentum Trade Ideas - Newser
GRI Bio reports six-week lung function data in Phase 2a study of GRI-0621 - MSN
News impact scoring models applied to GRI Bio Inc.July 2025 Volume & Community Consensus Picks - Newser
Short interest data insights for GRI Bio Inc.2025 Retail Activity & High Accuracy Trade Signal Alerts - Newser
Reversal indicators forming on GRI Bio Inc. stockRisk Management & Technical Pattern Alert System - Newser
How to use Fibonacci retracement on GRI Bio Inc.Earnings Beat & Accurate Entry and Exit Point Alerts - Newser
GRI Bio Inc. stock volume spike explained2025 Key Lessons & Risk Controlled Stock Alerts - Newser
Advanced analytics toolkit walkthrough for GRI Bio Inc.Quarterly Profit Review & Daily Growth Stock Investment Tips - Newser
Is GRI Bio Inc. stock entering bullish territoryWeekly Profit Summary & Community Verified Watchlist Alerts - Newser
Key External Factors That Drive GRI Bio Inc. Stock Price MovementsEarnings Growth Summary & Entry Point Strategy Guides - Newser
GRI Bio’s Stock Soars: Hidden Potential or Passing Phase? - StocksToTrade
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
GRI Bio Says Data Show No Lung Function Decline in Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis - MarketScreener
Will GRI Bio’s Stock Rise After Innovative Unveiling? - timothysykes.com
No Lung Function Decline: GRI Bio's Novel IPF Treatment Shows Promise in Phase 2a Trial Results - Stock Titan
How to use a screener to detect GRI Bio Inc. breakoutsQuarterly Market Review & Comprehensive Market Scan Reports - Newser
Is now a turning point for GRI Bio Inc.Market Activity Report & Advanced Swing Trade Entry Plans - Newser
Does GRI Bio Inc. fit your quant trading modelJuly 2025 Momentum & Community Supported Trade Ideas - Newser
Quantitative breakdown of GRI Bio Inc. recent move2025 Key Highlights & AI Forecast for Swing Trade Picks - Newser
What indicators show strength in GRI Bio Inc.Weekly Trend Summary & Daily Volume Surge Signals - Newser
Options Data Show Bullish Bias in GRI Bio Inc.Long Setup & Advanced Swing Trade Entry Plans - beatles.ru
Exit strategy if you’re trapped in GRI Bio Inc.July 2025 Momentum & Risk Managed Investment Entry Signals - Newser
Technical Charts Suggest Momentum Shift in GRI Bio Inc.July 2025 Short Interest & Growth Focused Stock Reports - beatles.ru
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):